Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
30 avr. 2024 08h38 HE
|
Fractyl Health, Inc.
Fractyl Health Announces Multiple Presentations at DDW 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
20 févr. 2024 08h38 HE
|
Fractyl Health, Inc.
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
Lyophilized Injectable Market Predicted to Reach USD 5 billion by 2031, Registering at a 5% CAGR | Exclusive Report by Transparency Market Research
29 août 2023 07h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global market for lyophilized injectable is anticipated to advance with almost a 5%...
Lindora taps retail and health industry veteran Colleen Lewis as new CEO, announces new metabolic health services
18 juil. 2023 09h15 HE
|
Lindora Clinic
IRVINE, July 18, 2023 (GLOBE NEWSWIRE) -- Lindora Clinic, a leading weight management and metabolic health company, today announced the appointment of Colleen Lewis as its chief executive officer...
Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
20 mars 2023 06h55 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the...
Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
07 mars 2023 06h57 HE
|
Synlogic, Inc.
– Podium presentation on Phase 2 phenylketonuria (PKU) data – – Poster presentations on Phase 1 homocystinuria (HCU) data and HCU preclinical data – CAMBRIDGE, Mass., March 07, 2023 (GLOBE...
Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
15 déc. 2022 19h01 HE
|
Sosei Group Corporation
New agreement leverages Sosei Heptares’ GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and therapeutic area expertiseSosei Heptares eligible...
Human Microbiome Market is expected to foster up to a landmark of USD 1318.72 Million by 2030 with a CAGR value of around 31.08%.
24 mai 2022 10h39 HE
|
STRATEGIC MARKET RESEARCH LLP
New York, United States, May 24, 2022 (GLOBE NEWSWIRE) -- A Human Microbiome comprises archaea, viruses, bacteria, & eukaryotes which reside within & outside our body system. These organisms...
Inventiva annonce que la FDA accepte sa demande d’« Investigational New Drug » pour l’essai clinique de Phase II combinant lanifibranor et empagliflozine chez des patients atteints de la NASH et de diabète de type 2
08 mars 2022 02h00 HE
|
INVENTIVA
L’évaluation de la Food and Drug Administration (FDA) est favorable à la poursuite de l’essai clinique combiné LEGEND Le lancement de l’étude est prévu pour S1 2022 et la publication des premiers...
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
08 mars 2022 02h00 HE
|
INVENTIVA
FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed The initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023 ...